{
 "edition": "20261104-18",
 "language": "zh-Hant",
 "period_start": "2026-11-04T18:00:00+09:00",
 "period_end": "2026-11-04T21:00:00+09:00",
 "page": 4,
 "pages": 4,
 "received_in_period": 301,
 "listed_in_period": 301,
 "description": "這裡一次整合 2 個國家／地區的新聞與公告：台灣 4 個來源 175 條、日本 1 個來源 126 條。每 180 分鐘一期，這期入庫的所有來源、每一條都列出，附原文網址。",
 "countries": [
  {
   "code": "TW",
   "name": "台灣",
   "items": 175,
   "sources": 4
  },
  {
   "code": "JP",
   "name": "日本",
   "items": 126,
   "sources": 1
  }
 ],
 "number_of_items": 1,
 "items": [
  {
   "id": 3734355,
   "anchor": "n3734355",
   "permalink": "https://ainews.idaeo.ai/180m/20261104-18/index-zh-Hant-p4.html#n3734355",
   "title": "中國全國53家醫院成立細胞與基因治療中心（附數據分析）-環球生技月刊",
   "title_state": "source",
   "summary": "截至2026年10月，中國全國53家公立三甲醫院建成57個細胞與基因治療（CGT）實體中心，主要集中於北京、廣州等一線城市。技術路線以免疫細胞治療為主，腫瘤為核心應用場景；企業端項目備案占比顯著上升，顯示創新潛力。",
   "summary_state": "source",
   "facts": [
    {
     "text": "53家公立三甲醫院",
     "state": "source",
     "quote": "53家公立三甲醫院"
    },
    {
     "text": "57個符合獨立建制標準的CGT實體中心",
     "state": "source",
     "quote": "57個符合獨立建制標準的CGT實體中心"
    },
    {
     "text": "截至2026年10月",
     "state": "source",
     "quote": "截至2026年10月"
    },
    {
     "text": "占總數的40.4%",
     "state": "source",
     "quote": "占總數的40.4%"
    },
    {
     "text": "僅36.8%的CGT中心公開院企合作",
     "state": "source",
     "quote": "僅36.8%的CGT中心公開院企合作"
    },
    {
     "text": "10月的60%",
     "state": "source",
     "quote": "10月的60%"
    }
   ],
   "companies": [
    "基因慧",
    "環球生技月刊"
   ],
   "published_at": "2026-10-30T01:00:00+09:00",
   "source_type": "gbimonthly",
   "source_name": "環球生技月刊",
   "country": "TW",
   "country_name": "台灣",
   "source_language": "zh-TW",
   "url": "https://news.gbimonthly.com/tw/invest/show.php?num=90995&kind=4",
   "link_level": "source",
   "link_label": "原文",
   "site_url": null,
   "merged_count": 1,
   "merged_ids": [],
   "merged_urls": []
  }
 ]
}